Email this article PARP inhibitors are a new area in the treatment of breast cancer
- Authors: Letyagin V.P.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 4 (2010)
- Pages: 4-5
- Section: MAMMOLOGY. TOPICAL ISSUE
- Published: 29.11.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/260
- DOI: https://doi.org/10.17650/1994-4098-2010-0-4-4-5
- ID: 260
Cite item
Full Text
Abstract
The paper considers the use of poly(ADP-ribose)-polymerase inhibitors in therapy for breast and ovarian cancer. Particular attention is given to drugs, such as olaparib and BSI-201. It is noted that the emergence of drugs of this class, of course, holds great promise for using remedial measures and gives certain hopes for their optimization.
About the authors
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: levipa@mail.ru
Russian Federation
References
Supplementary files
